Mr. Tony Allen Clark, M.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4251 W Cemetery Rd, Canyon, TX 79015 Phone: 806-655-7960 |
Christopher Guevara, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 907 23rd St, Canyon, TX 79015 Phone: 806-655-6823 Fax: 806-655-6823 |
Holly K Waggoner, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 907 23rd St, Canyon, TX 79015 Phone: 806-655-6824 Fax: 806-655-6823 |
Spencer Church, PT, DPT Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 907 23rd St, Canyon, TX 79015 Phone: 806-655-6824 Fax: 806-655-6823 |
Mrs. Katherine Sheri Rogers, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 15 Hospital Drive, Canyon, TX 79015 Phone: 806-367-4887 |
Canyon Physical Therapy Physical Therapist Medicare: Medicare Enrolled Practice Location: 907 23rd St, Canyon, TX 79015 Phone: 806-655-6824 Fax: 806-655-6823 |
Mrs. Jennifer Marie Winfrey, P.T. Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 907 23rd St, Canyon, TX 79015 Phone: 806-655-6824 Fax: 806-655-6823 |
News Archive
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
New research published in the April 2011 issue of the Journal of Vascular Surgery®, the official publication of the Society for Vascular Surgery®, directly measured the radiation doses for patients and operators during complex endovascular procedures.
An 18-year follow-up study of postmenopausal women in the Women's Health Initiative trials has shown that the use of hormone therapy was not associated with any increased risk of all-cause, cardiovascular or cancer death.
› Verified 3 days ago